GlassScriptPhysician profile
Joonhye Kook
NPI 1639576325
$5,444.66
in general payments reported to CMS, 2019-2025
30 companies · $946 in 2025
The $946 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,073 · 2022: $1,021 · 2023: $1,254 · 2024: $1,151 · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,351.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,608.90 | 2021-2025 | |
| Amgen INC. | $629.46 | 2021-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $596.55 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Glaxosmithkline, LLC. | $376.65 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $363.07 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $317.25 | 2021-2024 | Mounjaro, Zepbound, Trulicity |
| Scilex Pharmaceuticals INC. | $289.26 | 2021-2025 | Ztlido |
| Astrazeneca Pharmaceuticals LP | $204.19 | 2021-2024 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $190.81 | 2023-2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $145.96 | 2021-2025 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.33 | 2022-2025 | Xifaxan |
| Esperion Therapeutics, INC. | $65.96 | 2021 | |
| Aimmune Therapeutics, INC. | $61.73 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $59.45 | 2022-2023 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $54.00 | 2022-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $52.99 | 2021-2022 | |
| Amarin Pharma, INC. | $51.70 | 2021 | |
| Eisai INC. | $38.75 | 2021-2022 | |
| Lundbeck LLC | $33.66 | 2024-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $28.66 | 2021 | |
| Neurocrine Biosciences, INC. | $28.47 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $27.26 | 2021 | |
| Medtronic, INC. | $26.06 | 2022 | |
| Sanofi Pasteur INC. | $21.50 | 2023 | |
| Astellas Pharma US INC | $18.15 | 2023 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $15.91 | 2022 | |
| Exact Sciences Corporation | $15.42 | 2023 | Cologuard Collection Kit |
| Vivus LLC | $13.86 | 2021 | |
| Eyevance Pharmaceuticals LLC | $11.85 | 2021 | |
| Hikma Pharmaceuticals USA | $11.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joonhye Kook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.